173 related articles for article (PubMed ID: 34365543)
1. Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
Choi Y; Meissner HC; Hampp C; Park H; Winterstein AG
Eur J Pediatr; 2022 Feb; 181(2):841-845. PubMed ID: 34365543
[TBL] [Abstract][Full Text] [Related]
2. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
[TBL] [Abstract][Full Text] [Related]
3. Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization.
Choi Y; Meissner HC; Hampp C; Park H; Brumback B; Winterstein AG
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):317-325. PubMed ID: 32978942
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
5. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
7. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
8. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
Zembles TN; Gaertner KM; Gutzeit MF; Willoughby RE
Am J Health Syst Pharm; 2016 Mar; 73(6):405-8. PubMed ID: 26953285
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
[TBL] [Abstract][Full Text] [Related]
10. Adherence to the 2014 American Academy of Pediatrics palivizumab prophylaxis recommendations.
Sierra CM; Park A; Eum E; Garcia G; Lopez M; Daniel SN; Bahjri K; Parbuoni KA
Pediatr Pulmonol; 2021 May; 56(5):1121-1126. PubMed ID: 33314771
[TBL] [Abstract][Full Text] [Related]
11. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.
Wu P; Escobar GJ; Gebretsadik T; Carroll KN; Li SX; Walsh EM; Mitchel EF; Sloan C; Dupont WD; Yu C; Horner JR; Hartert TV
Am J Epidemiol; 2018 Jul; 187(7):1490-1500. PubMed ID: 29351636
[TBL] [Abstract][Full Text] [Related]
14. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
15. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
[TBL] [Abstract][Full Text] [Related]
16. Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.
Winterstein AG; Choi Y; Meissner HC
JAMA Pediatr; 2018 Feb; 172(2):154-160. PubMed ID: 29204660
[TBL] [Abstract][Full Text] [Related]
17. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
18. Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age.
Zembles TN; Bushee GM; Willoughby RE
J Pediatr; 2019 Jun; 209():125-129. PubMed ID: 30952507
[TBL] [Abstract][Full Text] [Related]
19. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
20. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
Prais D; Schonfeld T; Amir J;
Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
